1
|
Cheng Y, Yang S, Shen B, Zhang Y, Zhang X, Liu T, Xu S, Sui J, Yin L, Pu Y, Liang G. Molecular characterization of lung cancer: A two-miRNA prognostic signature based on cancer stem-like cells related genes. J Cell Biochem 2019; 121:2889-2900. [PMID: 31692042 DOI: 10.1002/jcb.29525] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Accepted: 10/10/2019] [Indexed: 12/13/2022]
Abstract
Lung cancer is one of the deadliest cancers worldwide. To increase the survival rate of lung cancer, it is necessary to explore specific prognosis markers. More and more evidence finds that noncoding RNA is closely associated with the survival of lung cancer, and cancer stem cells (CSCs) also play a significant role in the progress of lung cancer. The objective of this study is to find CSLCs genes that affect the prognosis of lung cancer. The differential expression of long noncoding RNAs (lncRNAs), microRNAs (miRNAs), messenger RNAs (mRNAs) in the Cancer Genome Atlas (TCGA) database and differential expression data from microarray of CD326+ and CD326- A549 cell are intersected to identify stable and consistent expression genes (2 lncRNAs, 15 miRNAs, and 134 mRNAs). The intersection of lncRNAs and miRNAs is analyzed by univariate and multivariate Cox regression to obtained prognostic genes. Two miRNAs (miR-30b-5p and miR-29c-3p) are significantly correlated with the overall survival rate. Then using these two miRNAs to construct a risk score model as a prognosis signature of lung cancer. Subsequently, we analyzed the association between two miRNAs and clinical information of lung cancer patients, of which T stage, Neoplasm cancer and risk score (P < .05) can be used as independent prognostic indicators of lung cancer. Finally, target genes of 2 miRNAs and 134 mRNAs were annotated with Gene Ontology and analyzed with Kyoto Encyclopedia of Genes and Genomes pathway, and verified with the GEO database. In summary, this study illustrates the role of miRNAs in the promotion of lung cancer by CSCs, which is important to find molecular biomarkers of lung cancer.
Collapse
Affiliation(s)
- Yanping Cheng
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Sheng Yang
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Bo Shen
- Department of Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
| | - Yan Zhang
- Department of Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
| | - Xiaomei Zhang
- Department of Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
| | - Tong Liu
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Siyi Xu
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Jing Sui
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Lihong Yin
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Yuepu Pu
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Geyu Liang
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China
| |
Collapse
|
2
|
Wood kraft pulp supplementation alters the rumen fermentation characteristics and epithelial transcriptomes in Holstein cattle during the high-grain diet challenge. Anim Feed Sci Technol 2019. [DOI: 10.1016/j.anifeedsci.2019.114292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
3
|
Zhang W, Jia J, Liu Z, Si D, Ma L, Zhang G. Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0. BMC Pulm Med 2019; 19:93. [PMID: 31088429 PMCID: PMC6518454 DOI: 10.1186/s12890-019-0836-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 03/24/2019] [Indexed: 12/21/2022] Open
Abstract
Background Sepsis biomarkers have limited specificity and sensitivity. Few studies have investigated microRNA (miRNA) biomarkers for sepsis secondary to pneumonia. This study aims to investigate the diagnostic and prognostic values of miRNAs in sepsis secondary to pneumonia. Methods Sepsis 3.0 was used to diagnose sepsis. Screening was performed through the Agilent miRNA chip technology by using the following criteria: p < 0.05, fold ≥2 or < 0.5, or copy number > 50 change. This study recruited 52 patients with pneumonia, including 31 males (59.6%) and 21 females (40.4%), 44 patients with sepsis secondary to pneumonia were diagnosed via Sepsis 3.0 (34 [77.3%] males and 10 [22.7%] females), and 21 healthy controls were used for miRNA verification. The miRNA levels were detected through fluorescence real-time quantitative polymerase chain reaction (qRT-PCR). Results: Fluorescence qRT-PCR detection showed that the miR-7110-5p and miR-223-3p expression levels in both patient groups were upregulated compared with those in the healthy controls. The expression levels differed between patients with pneumonia and those with sepsis secondary to pneumonia. The sensitivity and specificity of miR-7110-5p to differentiate sepsis from healthy controls were 84.2 and 90.5%, whereas those of miR-223-3p were 82.9 and 100%, respectively. Multivariate analysis of variance suggested that the presence of sepsis affected the miR-223-3p level (p = 0.041), whereas the presence of sepsis (p = 0.000) and the underlying disease (p = 0.025) influenced the miR-7110-5p level. Conclusions MiR-223-3p could be utilized to predict sepsis secondary to pneumonia.
Collapse
Affiliation(s)
- Wenping Zhang
- Department of Respiratory and Critical Care Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.,Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, Zhengzhou, 450052, Henan, China
| | - Jianchao Jia
- Department of Respiratory and Critical Care Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Zi Liu
- Department of Respiratory and Critical Care Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Dan Si
- Department of Respiratory and Critical Care Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Lijun Ma
- Department of Respiratory and Critical Care Medicine, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
| | - Guojun Zhang
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, Zhengzhou, 450052, Henan, China.
| |
Collapse
|
4
|
Wang K, Tan SL, Lu Q, Xu R, Cao J, Wu SQ, Wang YH, Zhao XK, Zhong ZH. Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer. THE AMERICAN JOURNAL OF CHINESE MEDICINE 2018; 46:1357-1368. [PMID: 30149755 DOI: 10.1142/s0192415x18500714] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Bladder cancer has a high recurrence rate and requires adjuvant intravesical management after surgery. The use of traditional agents for bladder cancer therapy is constrained by their toxicity and limited efficacy. This emphasizes the need for the development of safer, more effective compounds such as instillation agents. Curcumin is the major component of turmeric, the powdered root of Curcuma longa, which is known for its anti-inflammatory, anti-oxidant and anticancer properties. First, a microarray profiling and qPCR analysis were conducted in the T24 and SV-HUC-1 cell lines. Then, we examined the potential tumorigenicity of miR-7641 in the T24 and SV-HUC-1 cell lines with or without curcumin. Western blot analysis showed that p16 is a target of miR-7641 in T24 cells. We found that, for the first time, curcumin directly downregulates a tumor-promoting microRNA (miRNA), miR-7641, in bladder cancer, which has tumor-promoting characteristics. Curcumin induces the downregulation of miR-7641 and subsequent upregulation of p16 which is a target of miR-7641 at the post-transcriptional level, which leads to the decreased invasion and increased apoptosis of bladder cancer cells. This is the first report to show a direct effect of curcumin on inducing changes in a miRNA suppressor with direct anticancer consequences in bladder cancer. Our study shows that curcumin may be a candidate agent for the clinical management of non-muscle-invasive bladder cancer.
Collapse
Affiliation(s)
- Kai Wang
- * Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China.,‡ Department of Pharmacy, Hunan Provincial People's Hospital, Changsha, Hunan 410011, P. R. China
| | - Sheng-Lan Tan
- * Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Qiong Lu
- * Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Ran Xu
- † Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Jian Cao
- § Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410006, P. R. China
| | - Shui-Qing Wu
- † Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Yin-Huai Wang
- † Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Xiao-Kun Zhao
- † Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| | - Zhao-Hui Zhong
- † Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P. R. China
| |
Collapse
|
5
|
In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases. PLoS One 2018; 13:e0194612. [PMID: 29579063 PMCID: PMC5868815 DOI: 10.1371/journal.pone.0194612] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2017] [Accepted: 03/06/2018] [Indexed: 01/16/2023] Open
Abstract
Protein myristoylation is a key protein modification carried out by N-Myristoyltransferase (NMT) after Methionine aminopeptidase 2 (MetAP2) removes methionine from the amino-terminus of the target protein. Protein myristoylation by NMT augments several signaling pathways involved in a myriad of cellular processes, including developmental pathways and pathways that when dysregulated lead to cancer or immune dysfunction. The emerging evidence pointing to NMT-mediated myristoylation as a major cellular regulator underscores the importance of understanding the framework of this type of signaling event. Various studies have investigated the role that myristoylation plays in signaling dysfunction by examining differential gene or protein expression between normal and diseased states, such as cancers or following HIV-1 infection, however no study exists that addresses the role of microRNAs (miRNAs) in the regulation of myristoylation. By performing a large scale bioinformatics and functional analysis of the miRNAs that target key genes involved in myristoylation (NMT1, NMT2, MetAP2), we have narrowed down a list of promising candidates for further analysis. Our condensed panel of miRNAs identifies 35 miRNAs linked to cancer, 21 miRNAs linked to developmental and immune signaling pathways, and 14 miRNAs linked to infectious disease (primarily HIV). The miRNAs panel that was analyzed revealed several NMT-targeting mRNAs (messenger RNA) that are implicated in diseases associated with NMT signaling alteration, providing a link between the realms of miRNA and myristoylation signaling. These findings verify miRNA as an additional facet of myristoylation signaling that must be considered to gain a full perspective. This study provides the groundwork for future studies concerning NMT-transcript-binding miRNAs, and will potentially lead to the development of new diagnostic/prognostic biomarkers and therapeutic targets for several important diseases.
Collapse
|
6
|
Hu J, Guo X, Yang L. Morin inhibits proliferation and self-renewal of CD133 + melanoma cells by upregulating miR-216a. J Pharmacol Sci 2018; 136:114-120. [PMID: 29496393 DOI: 10.1016/j.jphs.2018.02.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 11/19/2017] [Accepted: 11/21/2017] [Indexed: 12/18/2022] Open
Abstract
Melanoma is one of the most malignant skin tumors with high mortality rate. Morin has been reported to treat several cancers. However, whether or how Morin affects melanoma progression is still poorly understood. Either Morin treatment or miR-216a overexpression reduced cell viability, sphere formation ability and expressions of stem cell marker genes CD20, CD44, CD133 and Wnt-3A. MiR-216a was induced by Morin treatment in CD133+ melanoma cells. Melanoma xenograft model treated by Morin showed reduced tumor size, weight as well as expressions of stemness markers and Wnt-3A. Inhibition of the stemness marker gene expressions in CD133+ melanoma cells is mediated by downregulating Wnt-3A through miR-216a. MiR-216a and Wnt-3A may potentially serve as clinical biomarkers of melanoma, and Morin may contribute to the treatment of melanoma.
Collapse
Affiliation(s)
- Jia Hu
- Department of Dermatology, Wuxi No.2 People's Hospital, No.68 Zhongshan Road, Chongan District, Wuxi 214000, Jiangsu Prov., China
| | - Xuedan Guo
- Department of Oncology, Wuxi No.2 People's Hospital, No.68 Zhongshan Road, Chongan District, Wuxi 214000, Jiangsu Prov., China
| | - Lijia Yang
- Department of Dermatology, Wuxi No.2 People's Hospital, No.68 Zhongshan Road, Chongan District, Wuxi 214000, Jiangsu Prov., China.
| |
Collapse
|
7
|
Wang, DC, Wang, W, Zhu, B, Wang X. Lung Cancer Heterogeneity and New Strategies for Drug Therapy. Annu Rev Pharmacol Toxicol 2018; 58:531-546. [PMID: 28977762 DOI: 10.1146/annurev-pharmtox-010716-104523] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Diane C. Wang,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - William Wang,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - Bijun Zhu,
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| | - Xiangdong Wang
- Zhongshan Hospital Institute of Clinical Science, Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai 200032, China
| |
Collapse
|
8
|
Abraityte A, Vinge LE, Askevold ET, Lekva T, Michelsen AE, Ranheim T, Alfsnes K, Fiane A, Aakhus S, Lunde IG, Dahl CP, Aukrust P, Christensen G, Gullestad L, Yndestad A, Ueland T. Wnt5a is elevated in heart failure and affects cardiac fibroblast function. J Mol Med (Berl) 2017; 95:767-777. [PMID: 28357477 DOI: 10.1007/s00109-017-1529-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 03/13/2017] [Accepted: 03/21/2017] [Indexed: 12/17/2022]
Abstract
Wnt signaling is dysregulated in heart failure (HF) and may promote cardiac hypertrophy, fibrosis, and inflammation. Blocking the Wnt ligand Wnt5a prevents HF in animal models. However, the role of Wnt5a in human HF and its functions in cardiac cells remain unclear. Here, we investigated Wnt5a regulation in HF patients and its effects on primary mouse and human cardiac fibroblasts. Serum Wnt5a was elevated in HF patients and associated with hemodynamic, neurohormonal, and clinical measures of disease severity. In failing human hearts, Wnt5a protein correlated with interleukin (IL)-6 and tissue inhibitor of metalloproteinase (TIMP)-1. Wnt5a messenger RNA (mRNA) levels were markedly upregulated in failing myocardium and both mRNA and protein levels declined following left ventricular assist device therapy. In primary mouse and human cardiac fibroblasts, recombinant Wnt5a dose-dependently upregulated mRNA and protein release of IL-6 and TIMP-1. Wnt5a did not affect β-catenin levels, but activated extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. Importantly, inhibition of ERK1/2 activation attenuated Wnt5a-induced release of IL-6 and TIMP-1. In conclusion, our results show that Wnt5a is elevated in the serum and myocardium of HF patients and is associated with measures of progressive HF. Wnt5a induces IL-6 and TIMP-1 in cardiac fibroblasts, which might promote myocardial inflammation and fibrosis, and thereby contribute to HF progression. KEY MESSAGES • Wnt5a is elevated in serum and myocardium of HF patients and is associated with measures of progressive HF. • In cardiac fibroblasts, Wnt5a upregulates interleukin (IL)-6 and tissue inhibitor of metalloproteinase (TIMP)-1 through the ERK pathway. • Wnt5a-mediated effects might promote myocardial inflammation and fibrosis, and thereby contribute to HF progression.
Collapse
Affiliation(s)
- Aurelija Abraityte
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway. .,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway. .,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.
| | - Leif E Vinge
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Department of Medicine, Diakonhjemmet Hospital, Postboks 23 Vinderen, 0319, Oslo, Norway
| | - Erik T Askevold
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway
| | - Tove Lekva
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Annika E Michelsen
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway
| | - Trine Ranheim
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Katrine Alfsnes
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Arnt Fiane
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Department of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Svend Aakhus
- Department of Cardiology, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Department of Circulation and Imaging, Faculty of Medicine, Norwegian University of Science and Technology, Postboks 8905 NTNU, Faculty of Medicine, 7491, Trondheim, Norway
| | - Ida G Lunde
- Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Postboks 4956 Nydalen, 0424, Oslo, Norway
| | - Christen P Dahl
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Department of Cardiology, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Pål Aukrust
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,K. G. Jebsen Inflammation Research Center, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,K. G. Jebsen Thrombosis Research and Expertise Center, The Arctic University of Norway, Postboks 6050 Langnes, 9037, Tromsø, Norway
| | - Geir Christensen
- Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Postboks 4956 Nydalen, 0424, Oslo, Norway
| | - Lars Gullestad
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Department of Cardiology, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Arne Yndestad
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,Center for Heart Failure Research, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,K. G. Jebsen Inflammation Research Center, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway
| | - Thor Ueland
- Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet; Postboks 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316, Oslo, Norway.,K. G. Jebsen Thrombosis Research and Expertise Center, The Arctic University of Norway, Postboks 6050 Langnes, 9037, Tromsø, Norway
| |
Collapse
|
9
|
Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release 2016; 244:14-23. [PMID: 27825958 PMCID: PMC5308909 DOI: 10.1016/j.jconrel.2016.11.001] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 10/12/2016] [Accepted: 11/02/2016] [Indexed: 01/27/2023]
Abstract
Glioblastoma multiforme (GBM) remains the deadliest brain tumor in adults. GBM tumors are also notorious for drug and radiation resistance. To inhibit GBMs more effectively, polymalic acid-based blood-brain barrier crossing nanobioconjugates were synthesized that are delivered to the cytoplasm of cancer cells and specifically inhibit the master regulator serine/threonine protein kinase CK2 and the wild-type/mutated epidermal growth factor receptor (EGFR/EGFRvIII), which are overexpressed in gliomas according to The Cancer Genome Atlas (TCGA) GBM database. Two xenogeneic mouse models bearing intracranial human GBMs from cell lines LN229 and U87MG that expressed both CK2 and EGFR at different levels were used. Simultaneous knockdown of CK2α and EGFR/EGFRvIII suppressed their downstream prosurvival signaling. Treatment also markedly reduced the expression of programmed death-ligand 1 (PD-L1), a negative regulator of cytotoxic lymphocytes. Downregulation of CK2 and EGFR also caused deactivation of heat shock protein 90 (Hsp90) co-chaperone Cdc37, which may suppress the activity of key cellular kinases. Inhibition of either target was associated with downregulation of the other target as well, which may underlie the increased efficacy of the dual nanobioconjugate that is directed against both CK2 and EGFR. Importantly, the single nanodrugs, and especially the dual nanodrug, markedly suppressed the expression of the cancer stem cell markers c-Myc, CD133, and nestin, which could contribute to the efficacy of the treatments. In both tumor models, the nanobioconjugates significantly increased (up to 2-fold) animal survival compared with the PBS-treated control group. The versatile nanobioconjugates developed in this study, with the abilities of anti-cancer drug delivery across biobarriers and the inhibition of key tumor regulators, offer a promising nanotherapeutic approach to treat GBMs, and to potentially prevent drug resistance and retard the recurrence of brain tumors.
Collapse
Affiliation(s)
- Szu-Ting Chou
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Rameshwar Patil
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Anna Galstyan
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Pallavi R. Gangalum
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Webster K. Cavenee
- Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, California, USA
| | - Frank B. Furnari
- Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, California, USA
| | - Vladimir A. Ljubimov
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alexandra Chesnokova
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Andrei A. Kramerov
- Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Hui Ding
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Vida Falahatian
- Duke University School of Medicine, Department of Biostatistic and Bioinformatics Clinical Research Training Program ( CRTP )
| | | | - Irving Fox
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Keith L. Black
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Eggehard Holler
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alexander V. Ljubimov
- Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Julia Y. Ljubimova
- Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
10
|
Ruiz Esparza-Garrido R, Rodríguez-Corona JM, López-Aguilar JE, Rodríguez-Florido MA, Velázquez-Wong AC, Viedma-Rodríguez R, Salamanca-Gómez F, Velázquez-Flores MÁ. Differentially Expressed Long Non-Coding RNAs Were Predicted to Be Involved in the Control of Signaling Pathways in Pediatric Astrocytoma. Mol Neurobiol 2016; 54:6598-6608. [PMID: 27738870 DOI: 10.1007/s12035-016-0123-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Accepted: 09/12/2016] [Indexed: 12/17/2022]
Abstract
Expression changes for long non-coding RNAs (lncRNAs) have been identified in adult glioblastoma multiforme (GBM) and in a mixture of adult and pediatric astrocytoma. Since adult and pediatric astrocytomas are molecularly different, the mixture of both could mask specific features in each. We determined the global expression patterns of lncRNAs and messenger RNA (mRNAs) in pediatric astrocytoma of different histological grades. Transcript expression changes were determined with an HTA 2.0 array. lncRNA interactions with microRNAs and mRNAs were predicted by using an algorithm and the LncTar tool, respectively. Interactomes were constructed with the HIPPIE database and visualized with the Cytoscape platform. The array showed expression changes in 156 and 207 lncRNAs in tumors (versus the control) and in pediatric GBM (versus low-grade astrocytoma), respectively. Predictions identified lncRNAs that have putative microRNA binding sites, which might suggest that they function as sponges in these tumors. Also, lncRNAs were shown to interact with many mRNAs, such as Pleckstrin homology-like domain, family A, member 1 (PHLDA1) and sulfatase 2 (SULF2). For example, qPCR found long intergenic non-coding RNA regulator of reprogramming (linc-RoR) expression levels upregulated in pediatric GBM when they were compared with control tissues or with low-grade tumors. Meanwhile, PHLDA1 and ELAV-like RNA binding protein 1 (ELAV1) showed expression changes in tumors relative to the control. Our data showed many lncRNAs with expression changes in pediatric astrocytoma, which might be involved in the regulation of different signaling pathways.
Collapse
Affiliation(s)
- Ruth Ruiz Esparza-Garrido
- Functional Genomics Laboratory, Unit of Human Genetics Research, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Juan Manuel Rodríguez-Corona
- Functional Genomics Laboratory, Unit of Human Genetics Research, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Javier Enrique López-Aguilar
- Oncology Department, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Marco Antonio Rodríguez-Florido
- Oncology Department, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Ana Claudia Velázquez-Wong
- Functional Genomics Laboratory, Unit of Human Genetics Research, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Rubí Viedma-Rodríguez
- Developmental Biology Laboratory, Unit of Morphology and Cellular Function, Faculty of Higher Education Iztacala, National Autonomous University of Mexico, 54090, Tlalnepantla, State of Mexico, Mexico
| | - Fabio Salamanca-Gómez
- Health Research Coordination, National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico
| | - Miguel Ángel Velázquez-Flores
- Functional Genomics Laboratory, Unit of Human Genetics Research, Children's Hospital, "Dr. Silvestre Frenk Freund," National Medical Center Century XXI, Mexican Institute of Social Security (IMSS), 06720, Mexico City, Mexico.
| |
Collapse
|